Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
Allen Jeremias(St. Francis Hospital), Stephen G. Ellis(Université de Perpignan), Deepak L. Bhatt(Mount Sinai Hospital), Derek P. Chew, Abdulhay Albirini, Sorin J. Brener, A. Michael Lincoff(Cleveland Clinic), Eric J. Topol(Scripps Research Institute), Khaled M. Ziada(Cleveland Clinic)
Cited by 27
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Long COVID: major findings, mechanisms and recommendations
|Nature Reviews Microbiology|2023|4k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k